MedPath

Genetic Testing and Motivational Counseling for FH

Not Applicable
Active, not recruiting
Conditions
Hypercholesterolemia, Familial
Hypercholesterolemia, Familial, 2
Hypercholesterolemia, Autosomal Dominant, 3
Treatment Adherence and Compliance
Familial Hypercholesterolemia
Adherence, Medication
Hypercholesterolemia, Familial, 4
Apolipoprotein B-100, Familial Defective
Genetic Testing
Motivational Interviewing
Interventions
Diagnostic Test: Lipid analysis
Genetic: Genetic Testing
Other: Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)
Behavioral: Motivational Counseling
Other: Visit 1
Other: Visit 2
Other: Visit 3
Other: Visit 4
Registration Number
NCT04656028
Lead Sponsor
National Medical Research Center for Therapy and Preventive Medicine
Brief Summary

To date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of LDL-C in most patients with familial hypercholesterolemia (FH). However, the effectiveness of treatment of FH patients strongly depends on adherence to lipid-lowering therapy and to the healthy lifestyle, as well as the detection of the disease and the therapy prescription as early as possible, better in childhood. The aim of the study is to assess the impact of genetic testing and motivational counseling on the effectiveness of treatment and cascade screening in patients with FH.

Detailed Description

There are several tasks of the study:

1. To assess the effect of knowledge of patients with FH about the result of their FH genetic testing on the adherence to a healthy lifestyle and hypolipidemic therapy.

2. To assess the impact of knowledge of patients with FH about the result of their FH genetic testing on the effectiveness of cascade screening.

3. To assess the influence of motivational counseling of patients with FH on the adherence to a healthy lifestyle and hypolipidemic therapy.

4. To assess the impact of motivational counseling of patients with FH on the effectiveness of cascade screening.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
180
Inclusion Criteria
  • Probable or definite diagnosis of FH according to the Dutch criteria (6 points or more);
  • Signed informed consent;
Exclusion Criteria
  • Pregnancy or lactation at the time of enrollment
  • Established active severe infectious disease or severe hematologic, metabolic, gastrointestinal or endocrine dysfunctions (for example, uncontrolled thyroid dysfunction or uncontrolled diabetes mellitus) in the opinion of the investigator
  • Active liver disease
  • Estimated GFR≤ 30 ml / min / 1.73m2
  • Any other conditions at Visit 1 that, according to the investigator's opinion, render the patient ineligible for inclusion in the study, may interfere with the patient's participation in the study or patient's completion of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1 - without genetic testing; subgroup without motivational counselingVisit 1Group 1 - without genetic testing; subgroup without motivational counseling
Group 1 - without genetic testing; subgroup without motivational counselingVisit 2Group 1 - without genetic testing; subgroup without motivational counseling
Group 1 - without genetic testing; subgroup without motivational counselingVisit 3Group 1 - without genetic testing; subgroup without motivational counseling
Group 1 - without genetic testing; subgroup without motivational counselingLipid analysisGroup 1 - without genetic testing; subgroup without motivational counseling
Group 1 - without genetic testing; subgroup without motivational counselingConsultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)Group 1 - without genetic testing; subgroup without motivational counseling
Group 1 - without genetic testing; subgroup with motivational counselingVisit 1Group 1 - without genetic testing; subgroup with motivational counseling
Group 1 - without genetic testing; subgroup with motivational counselingVisit 2Group 1 - without genetic testing; subgroup with motivational counseling
Group 1 - without genetic testing; subgroup with motivational counselingVisit 3Group 1 - without genetic testing; subgroup with motivational counseling
Group 2 - with genetic testing; subgroup without motivational counselingVisit 1Group 2 - genetic testing has been performed; subgroup without motivational counseling.
Group 1 - without genetic testing; subgroup with motivational counselingLipid analysisGroup 1 - without genetic testing; subgroup with motivational counseling
Group 1 - without genetic testing; subgroup without motivational counselingVisit 4Group 1 - without genetic testing; subgroup without motivational counseling
Group 1 - without genetic testing; subgroup with motivational counselingConsultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)Group 1 - without genetic testing; subgroup with motivational counseling
Group 1 - without genetic testing; subgroup with motivational counselingVisit 4Group 1 - without genetic testing; subgroup with motivational counseling
Group 2 - with genetic testing; subgroup without motivational counselingConsultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)Group 2 - genetic testing has been performed; subgroup without motivational counseling.
Group 2 - with genetic testing; subgroup without motivational counselingVisit 3Group 2 - genetic testing has been performed; subgroup without motivational counseling.
Group 2 - with genetic testing; subgroup with motivational counselingMotivational CounselingGroup 2 - genetic testing has been performed; subgroup with motivational counseling.
Group 2 - with genetic testing; subgroup with motivational counselingConsultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)Group 2 - genetic testing has been performed; subgroup with motivational counseling.
Group 1 - without genetic testing; subgroup with motivational counselingMotivational CounselingGroup 1 - without genetic testing; subgroup with motivational counseling
Group 2 - with genetic testing; subgroup with motivational counselingVisit 1Group 2 - genetic testing has been performed; subgroup with motivational counseling.
Group 2 - with genetic testing; subgroup with motivational counselingVisit 2Group 2 - genetic testing has been performed; subgroup with motivational counseling.
Group 2 - with genetic testing; subgroup with motivational counselingVisit 4Group 2 - genetic testing has been performed; subgroup with motivational counseling.
Group 2 - with genetic testing; subgroup without motivational counselingGenetic TestingGroup 2 - genetic testing has been performed; subgroup without motivational counseling.
Group 2 - with genetic testing; subgroup without motivational counselingLipid analysisGroup 2 - genetic testing has been performed; subgroup without motivational counseling.
Group 2 - with genetic testing; subgroup without motivational counselingVisit 4Group 2 - genetic testing has been performed; subgroup without motivational counseling.
Group 2 - with genetic testing; subgroup without motivational counselingVisit 2Group 2 - genetic testing has been performed; subgroup without motivational counseling.
Group 2 - with genetic testing; subgroup with motivational counselingGenetic TestingGroup 2 - genetic testing has been performed; subgroup with motivational counseling.
Group 2 - with genetic testing; subgroup with motivational counselingLipid analysisGroup 2 - genetic testing has been performed; subgroup with motivational counseling.
Group 2 - with genetic testing; subgroup with motivational counselingVisit 3Group 2 - genetic testing has been performed; subgroup with motivational counseling.
Primary Outcome Measures
NameTimeMethod
Change in the number of relatives who underwent cascade screening3 months

Change in the number of relatives who underwent cascade screening (% of relatives out of all available relatives. Available relatives are those who are alive and live in the region of where the study is conducted (Moscow and Moscow region)

Change in the proportion of people adhering to the recommended physical activity3 months

Change in the proportion of people adhering to the recommended physical activity (according to the Global Physical Activity Questionnaire (GPAQ))

Change in the proportion of people adhering to drug therapy3 months

Change in the proportion of people adhering to drug therapy according to the questionnaire MARS-5

Change in the proportion of individuals adhering to the recommended dietary recommendations3 months

Change in the proportion of individuals adhering to the recommended dietary recommendations (according to 24-hour Dietary Recall and Food Frequency Questionnaires)

Change in the proportion of people who have reached the target level of LDL-Cholesterol3 months

Change in the proportion of people who have reached the target level of LDL-Cholesterol (target values of LDL-C according to the ESC Dislipidaemia Guidelines 2019)

Secondary Outcome Measures
NameTimeMethod
Change in the proportion of people adhering to drug therapy15 months

Change in the proportion of people adhering to drug therapy according to the questionnaire MARS-5

Change in the proportion of people who have reached the target level of LDL-Cholesterol15 months

Change in the proportion of people who have reached the target level of LDL-Cholesterol (target values of LDL-C according to the ESC Dislipidaemia Guidelines 2019)

Change in the proportion of people adhering to the recommended physical activity15 months

Change in the proportion of people adhering to the recommended physical activity (according to the Global Physical Activity Questionnaire (GPAQ))

Change in the proportion of individuals adhering to the recommended dietary recommendations15 months

Change in the proportion of individuals adhering to the recommended dietary recommendations (according to 24-hour Dietary Recall and Food Frequency Questionnaires)

Change in the number of relatives who underwent cascade screening15 months

Change in the number of relatives who underwent cascade screening (% of relatives out of all available relatives. Available relatives are those who are alive and live in the region of where the study is conducted (Moscow and Moscow region)

Trial Locations

Locations (1)

National Medical Research Centre for Therapy and Preventive Medicine of the Ministry of Health of Russia

🇷🇺

Moscow, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath